IMAC Holdings Inc.'s subsidiary, Ignite Proteomics LLC, has announced a research collaboration with Inova Health to utilize its Reverse Phase Protein Array (RPPA) technology. This collaboration aims to analyze tumor samples from patients with late-stage gastrointestinal cancers to aid in treatment decision-making. The agreement is expected to significantly contribute to Ignite Proteomics' revenue in 2025, as it involves analyzing up to 600 tumor samples to generate actionable biomarker data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IMAC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-027034), on September 10, 2025, and is solely responsible for the information contained therein.